Piramal Pharma

OMD India bags integrated AOR mandate for Piramal Consumer Healthcare

Piramal Pharma has appointed OMD India, part of Omnicom Media Group, as its integrated media agency after a multi-round pitch. OMD India will handle the marketing and media efforts for Piramal Pharma’s portfolio of over-the-counter (OTC) brands, including Lacto Calamine, Little’s, Tetmosol, Polycrol, and Women’s intimate health range. The agency will be responsible for enhancing the brand’s presence, driving consumer engagement, and creating an impact-driven marketing strategy to drive business growth.

OMD India will manage the account out of its Mumbai office, bringing its expertise in media and digital innovation to create a game plan to boost brand salience and drive business growth. Anisha Iyer, CEO of OMD India, noted that the partnership represents a significant opportunity to leverage the agency’s strategic acumen and market intelligence to elevate Piramal’s portfolio of brands to new heights.

This win is a significant milestone for OMD India, building on its recent success, including winning the integrated media mandate for HDFC Life in January 2025. The partnership with Piramal Pharma is expected to further strengthen OMD India’s presence in the market. With this move, Piramal Pharma aims to create a lasting impression on consumers across India and shape a future of sustained growth and impact.

Piramal Pharma reports a profitable second quarter, with revenue soaring 11% year-on-year as its bottom line turns green.

Piramal Pharma, a leading pharmaceutical company, has announced its quarterly results for the second quarter (Q2) of the fiscal year 2022-23. The company has reported a significant improvement in its bottomline, with a net profit of ₹643 crore, compared to a net loss of ₹242 crore in the same period last year. This marks a substantial turnaround, with the company’s bottomline turning green.

Revenue for the quarter has also seen a significant growth, rising by 11% year-on-year (YoY) to ₹2,346 crore. The company’s operating profit has also increased by 34% YoY to ₹841 crore, driven by a combination of higher sales and better operating leverage.

The company’s pharmaceuticals division, which accounts for the majority of its revenue, reported a 10% YoY growth in revenue to ₹2,134 crore. The division’s operating profit also saw a significant increase, rising by 32% YoY to ₹753 crore.

Piramal Pharma’s specialty solutions division, which includes its CRAMS (Contract Research and Manufacturing Services) and custom synthesis business, reported a revenue growth of 16% YoY to ₹212 crore. The division’s operating profit also saw a significant increase, rising by 45% YoY to ₹88 crore.

The company’s performance was driven by strong demand for its products, particularly in the US and Europe, as well as its ability to navigate supply chain challenges and inflationary pressures. Piramal Pharma’s management has attributed the company’s success to its focus on operational excellence, cost management, and strategic investments in research and development.

Commenting on the results, Piramal Pharma’s CEO, Ajay Piramal, said, “We are pleased to report a strong set of Q2 results, with significant growth in revenue and profitability. Our focus on operational excellence, cost management, and strategic investments in R&D has enabled us to navigate the challenging global environment and deliver a strong performance.”

Overall, Piramal Pharma’s Q2 results are a testament to the company’s ability to adapt to changing market conditions and deliver strong financial performance. The company’s focus on innovation, operational efficiency, and customer satisfaction is likely to drive its future growth and success.

Eye on key earnings announcements: TVS Motor, Piramal Pharma, JSW Energy, Hindustan Zinc, Hyundai and Cipla are among the companies set to release their Q3 results today – Industry Insights

Here is a summary of the Q3 results 2025 live updates in 400 words:

Major companies across sectors have released their third-quarter results for financial year 2024-25. The Q3 earnings season is expected to be another quarter of modest performance with Nifty 50 PAT growth at 5.8 per cent YoY. JM Financial has warned of downside risks to its FY25E EPS growth expectation of 5.1 per cent. According to their analysis, 49 per cent of companies in their universe are at risk of EPS cuts.

Several companies are releasing their Q3 results today, including TVS Motor Company, Hindustan Zinc, Hyundai Motor India, GMR Airports, Bajaj Auto, Cipla, UTI Asset Management Company, TTK Prestige, VIP Industries, and more. Live updates are available for these companies.

Bajaj Auto reported a profit rise of 8.02 per cent to Rs 2,195.65 crore, driven by strong growth in the auto replacement and auto exports market segments. Exide Industries reported a profit drop of 21.83 per cent to Rs 158.44 crore, mainly due to a slowdown in govt. capex and other macroeconomic factors.

JSW Infrastructure reported a profit rise of 31.56 per cent to Rs 329.76 crore, while CG Power reported a profit drop of 67.82 per cent to Rs 240.53 crore. Hyundai Motor reported a profit drop of 18.56 per cent to Rs 1,160.73 crore, citing challenges in the overall market.

Cipla reported a profit of Rs 1,570.51 crore, beating estimates, with a revenue growth of 7.10 per cent YoY. The company’s performance was driven by growth across all geographies, despite a supply challenge in the US.

Other companies releasing Q3 results today include Suzlon Energy, Star Health & Allied Insurance Company, Motilal Oswal Financial Services, Piramal Pharma, Novartis India, Modi Naturals, JSW Energy, Lloyds Metals and Energy, JSW Infrastructure, Mahindra & Mahindra Financial Services, and Mahanagar Gas.

Piramal Pharma’s Little’s takes a softer stance with Yami Gautam as brand ambassador, launching #SwitchToSofter campaign

Noise, a leading Indian brand, has released its latest flagship product in the audio segment, the Noise Airwave Max 5 Headphones. Building on the success of its predecessor, the Airwave Max 4, the new headphones offer enhanced sound quality, comfort, and functionality. Designed for audiophiles and multitaskers, the Noise Airwave Max 5 combines cutting-edge technology with an ergonomic design to provide an unparalleled listening experience.

The headphones feature high-fidelity acoustics, a 40mm driver, and adaptive hybrid active noise cancellation (ANC) of up to 50dB, allowing users to block out distractions and immerse themselves in their favorite content. With an impressive 80-hour battery life, users can enjoy uninterrupted audio for extended periods. The headphones also boast low latency of up to 30ms, making them ideal for gaming and entertainment, and 3D spatial audio delivers a theater-like sound experience with exceptional depth and precision.

Additional features include dual pairing functionality, allowing users to easily switch between two devices, and quad mic environmental noise cancellation technology for impeccable call quality. The headphones also feature Bluetooth 5.4 for faster transmission speeds, improved range, and effortless pairing.

The Noise Airwave Max 5 headphones are built to withstand active lifestyles, with an IPX5 rating providing reliable sweat and water resistance. With their premium aesthetic and intricate build, these headphones are designed to deliver a superior auditory experience and make a style statement. The Noise Airwave Max 5 headphones are now available for purchase, catering to those who seek innovation, style, and performance.